SYNC.L

Syncona Limited [SYNC.L] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

SYNC.L Stock Summary

Top 10 Correlated ETFs

SYNC.L

Top 10 Correlated Stocks

SYNC.L

In the News

SYNC.L Financial details

Company Rating
-
Market Cap
798.38M
Income
-165.38M
Revenue
-144.46M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1.21K
Optionable
No
Shortable
Yes
Earnings
08 Feb 2024
P/E
-9.84
Forward P/E
-
PEG
0.05
P/S
-11.44
P/B
0.66
P/C
-
P/FCF
-6189.6
Quick Ratio
0.73
Current Ratio
0.74
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.25
EPS next Y
-
EPS next Q
-
EPS this Y
-730.08%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
NAN%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
2.23%
SMA50
-0.9%
SMA100
-11.11%
Inst Own
-
Inst Trans
-
ROA
-7%
ROE
-6%
ROC
-0.06%
Gross Margin
100%
Oper. Margin
111%
Profit Margin
116%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
105.0-188.2
52W High
-51.86%
52W Low
-13.81%
RSI
53.14
Rel Volume
0.42
Avg Volume
963.07K
Volume
409.25K
Perf Week
3.19%
Perf Month
-3.72%
Perf Quarter
-15.42%
Perf Half Y
-17.73%
-
-
-
-
Beta
0.257
-
-
Volatility
2.24%, 3.4%
Prev Close
-2.9%
Price
90.5
Change
-4.65%

Something similar

Top by Market Cap
BRK-B
BRYN.DE
NVD.DE
BRH.DE
VTSAX
Top Correlated ETFs
XPHI.L
EPAB.L
FTEU.L
DJMC.L
NRJU.L
Top Correlated Stocks
ALCRB.PA
2020.HK
FCT.MI
SYSR.ST
ADDT-B.ST
Similar Market Cap
2270.HK
BWMN
MFCCX
AWE.L
NGL

Company Profile

Financial Services Asset Management
  • Volume Average 963.07K
  • Market Capitalization 798.38M
  • Employee 1.21K
  • CEO Mr. Thomas Henderson
  • Headquarters London,GB
  • IPO Date 2012-10-26
  • Website https://www.synconaltd.com

Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and fixed income markets across the globe. It targets attractive medium to long term returns by investing in leading long-only and alternative investment funds with proven managers and across multiple asset classes. The firm invests in separately managed account portfolios.